[go: up one dir, main page]

WO1988007379A1 - Procede microbiologique d'obtention de substances de reduction de tumeurs et d'anticorps tumoraux dans des eprouvettes - Google Patents

Procede microbiologique d'obtention de substances de reduction de tumeurs et d'anticorps tumoraux dans des eprouvettes Download PDF

Info

Publication number
WO1988007379A1
WO1988007379A1 PCT/DE1988/000142 DE8800142W WO8807379A1 WO 1988007379 A1 WO1988007379 A1 WO 1988007379A1 DE 8800142 W DE8800142 W DE 8800142W WO 8807379 A1 WO8807379 A1 WO 8807379A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumour
reducing substances
antibodies
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1988/000142
Other languages
German (de)
English (en)
Inventor
Karl-Heinz Maier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO1988007379A1 publication Critical patent/WO1988007379A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Definitions

  • Microbiological process for obtaining tumor reducing substances and tumor antibodies in a test tube is a process for obtaining tumor reducing substances and tumor antibodies in a test tube.
  • the invention relates to a microbiological method with the aid of which it is possible to produce substances with a specific effect for reducing tumors of the human or animal body and specific tumor antibodies outside the organism in a test tube.
  • the only thing of interest is the problem of biological or immunotherapy. It can be assumed as certain that the human or animal organism, with the help of its own defense system, would be able to fight its own tumor if its own immune system recognized the tumor as hostile to the body. Since tumor cells arise from the body's own cells, the immune system is either not stimulated at all or only minimally when tumors grow, so that tumor cells can continue to grow, until the organism is ultimately no longer functional.
  • the task is to produce substances which, in the subsequent therapeutic application, specifically seek out, kill and degrade tumors and their metastases without damaging the rest of the organism.
  • Specified tumor cells for example adenocarcinoma cells
  • Specified tumor cells are inactivated, for example by freezing and thawing, and added as a cell suspension with living reticuloendothelial system (RES), preferably bone marrow, from another living being and incubated for a few days at 40 ° C.
  • RES reticuloendothelial system
  • tumor cells and the bone marrow defense cells do not originate from the same organism, the tumor cells are recognized as foreign to the body and thus trigger defense reactions in the living bone marrow cells, in the course of which specific reactions - eg against adenocarcinoma cells - Tumor reducing substances and specific
  • Tumor antibodies are generated. By centrifuging the entire incubate, a tumor antiserum with the specific tumor antibodies is obtained as a clear supernatant. It is now a light, tumor-reducing substance to be introduced either as a dilution of the total incubate or the Turaorantiserum as an injection into the diseased organism.
  • the present invention extends solely to the microbiological procedure for the production of these tumor-reducing substances and tumor antibodies and the substance and the antibodies themselves and not to their therapeutic use, the benefits of which are subsequently illustrated in an experimental example for testing the effectiveness. It must be emphasized that the antibodies obtained in this way react purely specifically to the tumor tissue in question and otherwise have no side effects on other body tissues.
  • Patent protection is not claimed for therapeutic use, but only for the micro biological production method and the product obtained in this way.
  • the commercial benefit is therefore not with the treating doctor, but rather with suitable laboratories, e.g. in the pharmaceutical industry, which are able to produce these specific substances and bring them back to the market (hospitals, doctors, etc.) according to the applicable health regulations .
  • Treatment Surgical removal of the primary tumor (approximately hen size) and removal of a hazelnut-sized metastasis.
  • Weight loss no signs of any disease. Of the 5 metastases, three are neither visible nor palpable, 2 metastases are no longer visible, but can still be palpated as pea-sized tissue densifications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Afin d'obtenir des substances spécifiques de réduction de tumeurs, on mélange dans une éprouvette une suspension de cellules tumorales inactivées (par exemple des cellules d'adénocarcinomes) avec un système réticulo-endothélial vivant, de préférence la moëlle osseuse d'un autre être vivant. Etant donné que les cellules tumorales représentent des protéines étrangères pour les cellules de la moëlle osseuse de l'autre être vivant, on obtient après quelques jours sous une température d'incubation d'environ 40° C des réactions de défense au cours desquelles des substances spécifiques de réduction de tumeurs et des anticorps tumoraux sont produits. Ceux-ci peuvent alors être utilisés comme médicaments biologiques pour le traitement de tumeurs.
PCT/DE1988/000142 1987-03-25 1988-03-15 Procede microbiologique d'obtention de substances de reduction de tumeurs et d'anticorps tumoraux dans des eprouvettes Ceased WO1988007379A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3709715 1987-03-25
DEP3709715.6 1987-03-25
DE19873733001 DE3733001A1 (de) 1987-03-25 1987-09-30 Mikrobiologisches verfahren zur gewinnung von spezifischen tumor reduzierenden substanzen im reagenzglas
DEP3733001.2 1987-09-30

Publications (1)

Publication Number Publication Date
WO1988007379A1 true WO1988007379A1 (fr) 1988-10-06

Family

ID=25853867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1988/000142 Ceased WO1988007379A1 (fr) 1987-03-25 1988-03-15 Procede microbiologique d'obtention de substances de reduction de tumeurs et d'anticorps tumoraux dans des eprouvettes

Country Status (3)

Country Link
AU (1) AU1424688A (fr)
DE (1) DE3733001A1 (fr)
WO (1) WO1988007379A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048880A1 (fr) 2008-10-31 2010-05-06 北京以岭生物工程有限公司 Nitropyridinyléthylèneimine, composition pharmaceutique l'incluant, sa méthode de synthèse et ses applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086689A (en) * 1964-12-01 1967-10-11 Alkliam Chemicals Ltd Pharmaceutically active extracts of bone marrow
EP0003173A1 (fr) * 1978-01-11 1979-07-25 The Massachusetts General Hospital Procédé de préparation d'anticorps humains et composition les contenant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086689A (en) * 1964-12-01 1967-10-11 Alkliam Chemicals Ltd Pharmaceutically active extracts of bone marrow
EP0003173A1 (fr) * 1978-01-11 1979-07-25 The Massachusetts General Hospital Procédé de préparation d'anticorps humains et composition les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Band 84, Nr. 7, 16. February 1976, (Columbus, Ohio, US), R. Revoltella et al.: "In vitro immune response by murine bone marrow cells stimulated against soluble immune complexes", siehe Seite 316 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048880A1 (fr) 2008-10-31 2010-05-06 北京以岭生物工程有限公司 Nitropyridinyléthylèneimine, composition pharmaceutique l'incluant, sa méthode de synthèse et ses applications
US8609851B2 (en) 2008-10-31 2013-12-17 Beijing Yiling Bioengineering Co., Ltd. Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof
US8940770B2 (en) 2008-10-31 2015-01-27 Beijing Yiling Bioengineering Co., Ltd. Nitropyridinyl ethyleneimine compound, the pharmaceutical composition containing it, the preparation method and use thereof

Also Published As

Publication number Publication date
DE3733001A1 (de) 1988-10-06
AU1424688A (en) 1988-11-02
DE3733001C2 (fr) 1989-03-02

Similar Documents

Publication Publication Date Title
EP0859628A1 (fr) Medicament, notamment pour moduler la reponse immunitaire dans la lutte contre des virus, des tumeurs, des bacteries et des parasites
DE69725317T2 (de) Implantierbare agarose-kollagenkügelchen enthaltende zellen, die ein diffusionsfähiges biologisches produkt bilden und ihre verwendung
DE4242902A1 (de) Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie
EP1706157B1 (fr) Procede de fabrication de transplants de cellules discales et utilisation en tant que materiau de transplantation
EP1481055A1 (fr) Procede de traitement de tissus malades, degeneres ou endommages faisant appel a un tissu tridimensionnel obtenu in vitro associe a des cellules tissulaires et/ou des facteurs exogenes
WO1988007379A1 (fr) Procede microbiologique d'obtention de substances de reduction de tumeurs et d'anticorps tumoraux dans des eprouvettes
CH650154A5 (de) Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung.
DE3923848C2 (de) Das Demaskierungstraining für autologe Immunozyten gegen maskierte Tumorzellen in vitro
EP0889053B1 (fr) Préparations à base de BK-RiV pour le traitement de maladies prolifératives cellulaires
DE69433472T2 (de) Recognin-vakzine
DE434751C (de) Verfahren zur Herstellung von Antigonorrhoe-Frischvakzinen
DE832321C (de) Verfahren zur Gewinnung eines Arzneimittels zur Behandlung von auf hemmungslosem Wachstum von Zellen o. dgl. beruhenden Erkrankungen, wie Leukaemie usw.
DE4236064C2 (de) Selektiv-toxisches Mittel und seine Verwendung
WO2001009287A2 (fr) Procede de traitement de cellules par la pression
DE102018113041A1 (de) Implantierbares pharmazeutisches Erzeugnis
EP2155335B1 (fr) Composition pharmaceutique, utilisation de la composition pharmaceutique pour le traitement d'une tumeur du cerveau, procédé de fabrication de cette composition et kit contenant la composition pharmaceutique
EP4233886A1 (fr) Composition pharmaceutique pour le traitement d'une tumeur cérébrale
DE658531C (de) Verfahren zur Herstellung eines peroral wirksamen fluessigen Heilmittels
DE499512C (de) Verfahren zur Herstellung von oertlich anzuwendenden, aus Bakterienkulturen, z.B. Staphylokokken-, Streptokokkenkulturen usw. gewonnenen, selbst aber bakterienfreien, sterilen, hochbestaendigen Impfstoffen (Topovaccinen)
DE19745792C1 (de) Verfahren zum Gewinnen von Proteingemischen und Steuerungsfaktoren aus Wundgranulations-, Epithelisierungs- oder determiniertem Blastozystengewebe
DE495838C (de) Verfahren zur Herstellung fluessiger Kulturen zur Bereitung einer Acidophilusmilch
DE19811402A1 (de) Arzneimittel zur Behandlung von mit Tumorzellen befallenem Gewebe sowie Verfahren zur Herstellung eines solchen Arzneimittels
DE2802277A1 (de) Verfahren zur herstellung eines gegen boesartiges wachstum gerichteten immunologischen wirkstoffkomplexes aus zellen
EP0451357A1 (fr) Facteurs de pathogenèse de dermatophytes
ELLENBOGEN et al. Brain computer interface: the future has arrived

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR JP SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE